04 august 2022
Small European based Research and Development company intending to develop and register their first NCE targeting Non-Alcoholic Fatty Liver Disease (NAFLD) & Steatohepatitis (NASH).
This drug was not authorised anywhere in the world.
Go to our Events to register
Go to our News to get insights